Alteogen Inc
KOSDAQ:196170
Gross Margin
Alteogen Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
|
Alteogen Inc
KOSDAQ:196170
|
18.8T KRW |
62%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.4B USD |
70%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
62%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
139.3B USD |
78%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.6B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
120.7B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
69.9B USD |
87%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
33B EUR |
90%
|
Alteogen Inc
Glance View
In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Alteogen Inc's most recent financial statements, the company has Gross Margin of 62.3%.
You don't have any saved screeners yet